These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32176553)

  • 1. The potential role of big data in the detection of adverse drug reactions.
    Sultana J; Trifirò G
    Expert Rev Clin Pharmacol; 2020 Mar; 13(3):201-204. PubMed ID: 32176553
    [No Abstract]   [Full Text] [Related]  

  • 2. [Role and Applicability of Spontaneous Reporting Databases in Medical Big Data].
    Sakai T
    Yakugaku Zasshi; 2021; 141(2):165-168. PubMed ID: 33518634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China.
    Liu Y; Xu X; Yang J; Zhang Y; He M; Liao W; Wang N; Liu P
    Expert Opin Drug Saf; 2024 Jul; 23(7):893-904. PubMed ID: 38009292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it possible to identify risk factors for adverse drug reactions using a pharmacovigilance database based on spontaneous reporting?
    Noguchi Y; Yoshimura T
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5737. PubMed ID: 37985422
    [No Abstract]   [Full Text] [Related]  

  • 6. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of risk factors for adverse drug reactions in a pharmacovigilance database.
    Attelind S; Eriksson N; Sundström A; Wadelius M; Hallberg P
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5753. PubMed ID: 38169128
    [No Abstract]   [Full Text] [Related]  

  • 8. Big Data and Adverse Drug Reaction Detection.
    Harpaz R; DuMochel W; Shah NH
    Clin Pharmacol Ther; 2016 Mar; 99(3):268-70. PubMed ID: 26575203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?
    Svendsen K; Halvorsen KH; Vorren S; Samdal H; Garcia B
    Eur J Clin Pharmacol; 2018 Apr; 74(4):497-504. PubMed ID: 29255992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifteen years of patient reporting -what have we learned and where are we heading to?
    van Hunsel F; Härmark L; Rolfes L
    Expert Opin Drug Saf; 2019 Jun; 18(6):477-484. PubMed ID: 31030578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using real-world healthcare data for pharmacovigilance signal detection - the experience of the EU-ADR project.
    Patadia VK; Coloma P; Schuemie MJ; Herings R; Gini R; Mazzaglia G; Picelli G; Fornari C; Pedersen L; van der Lei J; Sturkenboom M; Trifirò G;
    Expert Rev Clin Pharmacol; 2015 Jan; 8(1):95-102. PubMed ID: 25487079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases.
    Leroy F; Dauxois JY; Théophile H; Haramburu F; Tubert-Bitter P
    BMC Med Res Methodol; 2014 Feb; 14():17. PubMed ID: 24490673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.
    Trifirò G; Sultana J; Bate A
    Drug Saf; 2018 Feb; 41(2):143-149. PubMed ID: 28840504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
    Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
    Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations on the use of different comparators in pharmacovigilance: A methodological review.
    Gravel CA; Douros A
    Br J Clin Pharmacol; 2023 Sep; 89(9):2671-2676. PubMed ID: 37226576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
    Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
    Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance - The next chapter.
    Moore N; Berdaï D; Blin P; Droz C
    Therapie; 2019 Dec; 74(6):557-567. PubMed ID: 31623850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mining heterogeneous networks with topological features constructed from patient-contributed content for pharmacovigilance.
    Yang CC; Yang H
    Artif Intell Med; 2018 Aug; 90():42-52. PubMed ID: 30093253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.